Imagine a future where the moment you’re born, a virtual avatar is created and steadily filled with personalised information ...
Morrow is now devoting his life to prostate cancer advocacy and urging other younger, high-risk men to get screened early. He ...
Median progression-free survival (PFS) increased from 7.4 months with stereotactic body radiotherapy (SBRT) to 17.6 months with the addition of 177 lutetium (Lu) PNT2002 targeting prostate-specific ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...
Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived ...
Prostate cancer stages explain how far cancer has spread. Stage 1 and 2 stay in the prostate and are highly treatable. Stage ...
Zacks Investment Research on MSN
GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent
GE HealthCare GEHC recently announced that it has signed an exclusive license agreement with medical imaging agents and products manufacturer, Lantheus Holdings, gaining access to the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback